<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03841136</url>
  </required_header>
  <id_info>
    <org_study_id>ALTN-SCLC-001</org_study_id>
    <nct_id>NCT03841136</nct_id>
  </id_info>
  <brief_title>Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer</brief_title>
  <official_title>Phase II Clinical Trial of Anlotinib Combined With Etoposide and Platinum in the Treatment of Extensive Stage Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the progression free survival of patients with extensive stage small cell lung&#xD;
      cancer treated with anlotinib combined with EP/CE regimen&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the progression free survival of patients with extensive stage small cell lung&#xD;
      cancer treated with anlotinib combined with EP/CE regimen To evaluate the safety,&#xD;
      tolerability, overall survival (OS), objective response rate (ORR), disease control rate&#xD;
      (DCR), and quality of life (QoL) of patients with extensive stage small cell lung cancer&#xD;
      treated with anlotinib&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>from the first cycle of treatment (day one) to two month after the last cycle</time_frame>
    <description>the progression free survival of patients with extensive stage small cell lung cancer treated with anlotinib combined with EP/CE regimen</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Extensive-stage Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>anlotinib combined with EP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>anlotinib combined with etoposide and platinum</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anlotinib</intervention_name>
    <description>anlotinib 12mg PO QD CBP(AUC 5mg/mL/min，or DDP（75mg/m2）D1 etoposide（100mg/m2）D1~D3</description>
    <arm_group_label>anlotinib combined with EP</arm_group_label>
    <other_name>etoposide and platinum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients volunteered to participate in the study and have signed the informed consent.&#xD;
&#xD;
          2. Histological or cytological diagnosis of extensive small cell lung cancer, and no&#xD;
             indication of radical surgery or radiotherapy.&#xD;
&#xD;
          3. There are measurable lesions defined by RECIST standard v1.1. A lesion can be&#xD;
             considered measurable only if the previously irradiated lesion has clear progression&#xD;
             after radiotherapy and the previous irradiated lesion is not the sole lesion.&#xD;
&#xD;
          4. Initially treated patients who have not received any systematic therapy before. If&#xD;
             have received postoperative adjuvant chemotherapy, the time to relapse is at least 6&#xD;
             months from the last adjuvant chemotherapy.&#xD;
&#xD;
        5）18~75 years old; ECOG PS score: 0~1 points; expected survival time is more than 3 months.&#xD;
&#xD;
        6）The main organs's function meets the following criteria within 14 days before treatment:&#xD;
&#xD;
          1. Routine blood test (without blood transfusion within 14 days): a) Hemoglobin (HB) ≥ 90&#xD;
             g / L; b) Absolute neutrophil (ANC) ≥ 1.5 × 109 / L; c) Platelets (PLT) ≥ 80×109/L&#xD;
&#xD;
          2. Biochemical examination: a) Total bilirubin (TBIL) ≤ 1.5 times of the upper limit of&#xD;
             the normal (ULN); b) Alanine aminotransferase (ALT) and aspartate aminotransferase AST&#xD;
             ≤ 2.5ULN.To patients with liver metastasis, ALT and AST ≤ 5ULN; c) Serum creatinine&#xD;
             (Cr) ≤ 1.5ULN or creatinine clearance (CCr) ≥ 60ml / min;&#xD;
&#xD;
          3. Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ the lower&#xD;
             limit of the normal (50%).&#xD;
&#xD;
        7）Patients with previously treated asymptomatic CNS metastases are allowed to participate&#xD;
        in this study if all of the following criteria are met: a) No need for continuous&#xD;
        corticosteroid therapy for CNS disease; b) No radiotherapy within 7 days prior to&#xD;
        enrollment treatment; c) Imaging examination from the end of radiotherapy to screening&#xD;
        period shows no CNS progression.&#xD;
&#xD;
        8）Women of childbearing age should agree to conduct contraception (such as intrauterine&#xD;
        devices, contraceptives or condoms) during the study and within 6 months after the end of&#xD;
        the study; and the serum or urine pregnancy test is negative within 7 days prior to study&#xD;
        enrollment and they must be non-lactating patients; Men should agree to conduct&#xD;
        contraception during the study and within 6 months after the end of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have been treated with anlotinib capsules in the past.&#xD;
&#xD;
          2. Patients who have previously received systemic chemotherapy, signal transduction&#xD;
             inhibitors, targeted therapies, hormone and endocrine therapy.&#xD;
&#xD;
          3. Patients with other malignant tumors occurred within 5 years prior to the enrollment,&#xD;
             except those with cured cervical carcinoma in situ and superficial bladder tumors [Ta&#xD;
             (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement&#xD;
             membrane)] , basal or squamous cell skin cancer, and localized prostate cancer and&#xD;
             ductal breast carcinoma in situ treated with radical surgery.&#xD;
&#xD;
          4. Unresolved toxicity due to any previous treatment above CTC AE (4.0) level 2 or&#xD;
             higher, excluding hair loss.&#xD;
&#xD;
          5. Patients with a variety of factors affecting oral medications (such as dyspahgia,&#xD;
             gastrointestinal resection, chronic diarrhea and intestinal obstruction, etc.)&#xD;
&#xD;
          6. Patients with symptomatic CNS metastases.&#xD;
&#xD;
          7. Patients with dysfucitonal coagulation (PT&gt;16s, APTT&gt;43s, TT&gt;21s, Fbg&lt;2g/L), and&#xD;
             bleeding tendency (the following condition must be met within 14 days before the&#xD;
             enrollment: the INR is within the normal range without using anticoagulants); Patients&#xD;
             treated with anticoagulants or vitamin K antagonists such as warfarin, heparin or the&#xD;
             like; Patients with International Normalized Ratio (INR) of less than1.5 are allowed&#xD;
             to use low-dose warfarin (1 mg orally, once daily) or aspirin (with a daily dose of no&#xD;
             more than 100 mg) for prophylactic purposes.&#xD;
&#xD;
          8. Patients with major surgical treatment, incisional biopsy or tremendous traumatic&#xD;
             injury within 28 days prior to the enrollment.&#xD;
&#xD;
          9. Patients with tumors that have invaded tissues surrounding vital blood vessels founded&#xD;
             in imaging or with a high probability of fatal bleeding due to the invasion of tumors&#xD;
             to vital blood vessels according to the judgements of the researchers during the&#xD;
             follow-up study.&#xD;
&#xD;
         10. Patients with uncontrolled pleural, pericardial, or peritoneal effusion requiring&#xD;
             repeated drainage.&#xD;
&#xD;
         11. Patients with any severe and/or uncontrolled disease, including:&#xD;
&#xD;
               1. Patients with unsatisfactory blood pressure control (systolic blood pressure &gt;150&#xD;
                  mmHg, diastolic blood pressure &gt;90 mmHg).&#xD;
&#xD;
               2. Patients with myocardial ischemia or myocardial infarction of Grade I of higher&#xD;
                  level, arrhythmia (including QTC ≥ 440ms) and congestive heart failure above&#xD;
                  Grade 2 (New York Heart Association (NYHA) classification).&#xD;
&#xD;
               3. Patients with active or uncontrolled severe infection (≥ CTC AE Level 2).&#xD;
&#xD;
               4. Patients with a history of immunodeficiency, including HIV-positive or other&#xD;
                  acquired, congenital immunodeficiency disease, or a history of organ&#xD;
                  transplantation.&#xD;
&#xD;
               5. Patients with poor control of diabetes (fasting blood glucose (FBG)&gt;10mmol/L).&#xD;
&#xD;
               6. Patients with urine protein ≥ ++ indicated by routine urine test, and confirmed&#xD;
                  24-hour urine protein quantitation &gt; 1.0 g.&#xD;
&#xD;
               7. Patients with seizures requiring treatment.&#xD;
&#xD;
         12. Patients with bleeding tendency or medical history regardless of severity; Patients&#xD;
             undergone bleeding events of a level ≥ CTCAE 3 within 4 weeks prior to the enrollment,&#xD;
             and with unhealed wounds, ulcers or fractures.&#xD;
&#xD;
         13. Patients undergone venous thrombosis events currently or within 6 months, such as&#xD;
             cerebrovascular accidents (including transient ischemic attacks), deep vein&#xD;
             thrombosis, and pulmonary embolism.&#xD;
&#xD;
         14. Patients with a history of psychotropic drug abuse from which they are unable to&#xD;
             abstain or with mental disorders.&#xD;
&#xD;
         15. Patients who have participated in other clinical trials of anti-tumor drugs within&#xD;
             four weeks.&#xD;
&#xD;
         16. Patients with severe disease that threaten the safety of themselves or affect the&#xD;
             completion of the study according to the investigators' judgment.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>wang jia lei, doctor</last_name>
    <phone>18017312369</phone>
    <email>haitunqiao@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wang jia lei, PD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 1, 2019</study_first_submitted>
  <study_first_submitted_qc>February 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>March 26, 2019</last_update_submitted>
  <last_update_submitted_qc>March 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Jialei Wang</investigator_full_name>
    <investigator_title>Attending</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

